Merlin Thomas

Professor Merlin Thomas is a leading clinician-scientist in the Department of Diabetes at Monash University’s Faculty of Medicine, Nursing and Health Sciences. He is internationally recognized for his research on diabetic complications, particularly diabetic kidney disease, and leads the Biochemistry of Diabetes Complications Laboratory. His work bridges molecular science and clinical practice, aiming to develop novel therapies and influence patient care and guidelines.

Research Interests:

• Diabetic complications and their molecular mechanisms
• Advanced glycation end-products (AGEs) and methylglyoxal in disease
• Chronic and diabetic kidney disease
• Translational research from bench to bedside
• Development of RNA-based and oligonucleotide therapeutics
• Cardiovascular complications in diabetes

His recent publications highlight a strong trend in targeting metabolic and epigenetic pathways in diabetic nephropathy, exploring RNA therapies for viral and cancer applications, and identifying biomarkers for kidney disease. These works reflect interdisciplinary efforts combining biochemistry, clinical trials, and pharmacology.

Scientific Recognition:

• Third-highest ranked expert globally in diabetic kidney disease
• Over 270 publications in top-tier journals (e.g., Diabetes, The Journal of Clinical Investigation)
• Chief Investigator in 18 research projects, including NHMRC-funded initiatives
• Contributor to international patents and clinical guidelines

Grants and Advising: He is Primary Chief Investigator on multiple active grants, including projects on splice-switching oligonucleotides for kidney disease and inhaled RNA therapies for SARS-CoV-2. While no students are listed, he collaborates extensively with leading researchers such as Mark Cooper, Joseph Pickering, and Sonia Davila. His leadership in the NHMRC Diabetes Complications CRE underscores his role in shaping national research directions.

Laboratory and Team: The Biochemistry of Diabetes Complications Laboratory at Monash University fosters multidisciplinary research, integrating molecular biology, physiology, and clinical data. The lab benefits from state-of-the-art infrastructure and collaborations across nephrology, endocrinology, and molecular therapeutics.